Extravasation of medications during peripheral intravenous (PIV) therapy can result in harm to pediatric patients. These medications have physical and/or biologic factors that cause tissue damage. To assist in clinical decisions when using these infusates, an evidence-based table of medications stratified by their relative risk of causing harm if extravasated was developed. Local data and experience, a systematic review of the pediatric literature, and measured pH and osmolality of common pediatric preparations of PIV infusates were used to create a 3-tiered table of PIV infusates categorized by relative risk of causing harm if extravasated.
The article was drafted and revised collaboratively, with substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data by all authors. Each author has seen and approved the submission of this version of the article and takes full responsibility for the article. P eripheral intravenous (PIV) insertion is one of the most common procedures undertaken for pediatric patients requiring short-term infusion therapy. Serious but uncommon risks with PIV therapy may result in predictable patient injury, and the patient safety and medicolegal consequences are well known to most institutions. PIV device is defined as any venous access device whose tip lies outside the right atrium, superior or inferior vena cava, or brachiocephalic veins.
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Infants and children pose challenges to optimal PIV management because of their limited communication abilities, unpredictable behavior and activity levels, and small vessel sizes. 1 Although extravasation with temporary injury and discomfort is a far too common occurrence, significant tissue injury resulting in skin grafts and/or fasciotomies as a complication of PIV therapy should not occur. 2, 3 For the purposes of this article, the authors define extravasation as any inadvertent administration or leakage of infusate into the extravascular tissue, 4 though they acknowledge that other definitions exist. 5, 6 The authors' organization is a quaternary care pediatric teaching hospital that treats more than 1 million patients per year. The hospital assembled a multidisciplinary team to create a plan to decrease the PIV extravasation rate and prevent associated permanent harm. This article presents an evidence-based table of medications, stratified according to risk of tissue damage if extravasated from a PIV, which was developed as part of that plan.
METHODS
The table was developed in 3 steps. First, local data from, and experience with, injuries due to PIV extravasation were used to draft a consensus list of medications stratified by risk for harm.
Next, a comprehensive, systematic search of the health care literature was conducted to address the question, "Which medications are associated with permanent harm in the context of PIV extravasation in children?" See Table 1 for details of the search strategy and selection criteria.
Finally, 4 physical or biologic factors of medications that cause tissue damage (extreme pH, osmolality, vasoactivity, and cytotoxicity) were evaluated to address the question, "What is the relative risk of harm of each medication for PIV extravasations in children?" (not including harm due solely to large extravasation volume). See Table 2 for definitions and characteristics of these factors.
Because pH and osmolality of a solution can change on the basis of the concentration of the drug and the diluent used, common pediatric preparations of PIV infusates were measured for actual pH and osmolality. See Table 3 for methods used for obtaining these measures.
RESULTS
The first step of the process resulted in a consensus version of the table to be used by clinicians. The table stratified the selected medications by risk into 3 colorcoded tiers (higher, intermediate, and lower risk) and was named the Red/Yellow/Green list.
The second step of the process added published evidence to enhance the accuracy of the list. Of the 65 selected articles that described permanent harm due to PIV extravasation, 75% were case reports, 90% of which were reports of 1 to 4 cases; 3% of the articles were randomized controlled trials of prevention or injury management interventions; and 22% were cohort studies, prospective and retrospective, and heterogeneous in intent, study size, and design. Eight additional articles were selected that contained lists of medications of known or suspected risk for injury due to extravasation. These lists were used to identify • Both acidic and alkaline substances can irritate vessel walls, damage cell proteins, and cause cell death 6, 7 • The pH of a solution can change on the basis of the concentration of the drug and the diluent used in the preparation of the intravenous mixture 7 • The pH levels of the solutions in the table were measured at the authors' facility using the most common pediatric preparation for each intravenous solution Osmolality
• A measure of the number of particles per kilogram of solvent 7 • Both hypotonic and hypertonic solutions can cause cell death due to shifts in intracellular solute concentration 7 • Isotonic solutions have an osmolality that approximates that of blood 7 • Osmolality of a solution can change on the basis of the concentration of the drug and the diluent used in the preparation of the intravenous mixture 7 • The osmolality levels of the solutions in the table were measured at the authors' facility using the most common pediatric preparation for each intravenous solution
Vasoactivity
• The ability of a drug to cause constriction of small peripheral vessels, including arterioles 6 • Reduced blood flow due to capillary constriction can lead to tissue necrosis 6 
Cytotoxicity
• The ability of a drug to cause cell damage or death directly, such as chemotherapeutic agents and sclerosing agents 6 medications carrying risk of harm on the basis of "expert opinion" when there were no specific published cases of harm for a particular medication. The published evidence guided a second draft of the Red/Yellow/ Green list, involving additions, deletions, and changes in risk tiers for some medications. Last, the measured pH and osmolality data for the most common PIV solutions given to patients at the authors' organization were evaluated with respect to the second draft of the Red/Yellow/Green list. These data guided further modification to finalize the list with additions, deletions, and changes in risk tiers for some medications ( Figure 1 and http://neiloz.com/vascular). Table 4 presents the risk-stratified list with details of the measured pH and osmolality for common pediatric preparations of PIV infusates with details of the published evidence support.
CLINICAL IMPLICATIONS
This comprehensive, pediatric-focused, evidence-based table of medications, categorized by relative risk of extravasation harm, is just 1 strategy to reduce PIV extravasations. This table is not meant to be used in isolation but, rather, in combination with additional strategies, such as proper nursing assessments and modifying risk factors for PIV extravasation. It is acknowledged, however, that even with optimal assessment and monitoring of PIVs, extravasations are inevitable.
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TABLE 3
Methods of pH and Osmolality Testing
Fresh solution for each product was prepared for each specified medication concentration and diluent.
pH
Oakton Model pHTestr2 was calibrated using GFS Chemicals buffer solution 10.0.
A 10-mL aliquot of medication was placed in the testing container, the pH probe was placed in the container and was allowed to equilibrate for 60 seconds, and the reading was recorded. The pH probe was rinsed, and the process was repeated for a second aliquot to confirm the initial reading for each sample. The complete process was repeated for each medication, with recalibration between products. 
• Ͼ950 mOsm/L in references (C harm) [40] [41] [42] • OSM in references unknown (F, C harm) In addition to using the table to determine the risk for a given PIV infusate, it can also be used to influence the choice of vascular access device most suited to the situation. Though harm from extravasation is a possibility with any intravenous delivery site, when a medication in the higher-risk tier is ordered, the authors advocate that consideration be given to the use of central access to reduce the risk of harm should extravasation occur. 81 The authors reasoned that if clinicians could be influenced by the Red/Yellow/Green list to consider and trend toward central access for delivery of higher-risk medications, the combination of improvements in PIV monitoring and changes in the prescribing habits of clinicians should result in a greater overall reduction of PIV-related harm than either strategy alone. The authors acknowledge that the clinical decision-making process is complex and must take into account the cost and risks of central vascular access, including PIV central catheters.
It should also be noted that although the medications in the lower-risk tier may seem more innocuous, any infusate has the potential to cause harm. Gross extravasation, even of normal saline, may result in serious harm including compartment syndrome, causing ischemia and loss of tissue or permanent loss of limb function. 76 In the search for evidence about the risk for medications that cause harm when extravasated from a PIV, several medications were reported that are no longer used in clinical practice. As new medications are approved, each will need to be rigorously assessed for risk of extravasation harm. Although case studies may increase awareness of a medication's potential for risk, well-designed research studies should be conducted to determine actual risk.
